In pharma, the biggest deals are increasingly won or lost before a formal process even begins. In this episode, Dr Andree Bates interviews Andrey Doronichev, co-founder and CEO of Bioptic, about the “intelligence gap” in business development, licensing, and corporate strategy, and why many companies are losing opportunities before they even know they’re competing.
To listen our podcast, Click here...
Write a comment ...
The following infographic shows how AI in Life Sciences is helping accelerate research and development through smarter data analytics, faster drug discovery, better clinical development, informed decision-making, and forward-thinking innovations. Eularis assists life sciences companies use AI to gain growth and transformation.
Enrolment isn’t a “soft” operational risk in drug development – it’s the hard constraint that quietly determines whether a promising asset reaches patients on time or bleeds value in limbo. In today’s clinical landscape, recruitment timelines are missed so routinely that it has become the norm rather than the exception, with widely cited analyses indicating that roughly 80% of trials experience delays driven by enrolment.
The life sciences sector is at a really critical crossroad. From pharmaceutical firms dealing with patent cliffs to biopharma groups racing to push new therapies into market, the pressure to innovate has just never been higher. And really, at the middle of all this shift sits artificial intelligence in life sciences — a tool that is changing, in practice, how research gets done, how drug candidates are built and tested, and how healthcare organisations manage sustainable growth.
The future of medical clinical research is kind of being rewritten already — not only in labs, but also in lines of code, machine learning models, and AI-led strategies that are shifting how trials are basically designed, carried out, and delivered. Eularis, a global leader in AI strategy for biopharma and life sciences with over 20 years of experience, sees this change as more than just a distant goal. It’s happening right now, like today.
This infographic on Artificial Intelligence in Pharma and Biotech highlights how AI is transforming drug discovery, clinical research, and patient care. Eularis provides innovative AI-driven solutions that help pharmaceutical and biotech companies improve efficiency, accelerate innovation, and support smarter healthcare decisions
Cell therapies have huge potential, but cost, complexity, and centralised manufacturing have kept many of them confined to last-line use. In this episode, Dr Andree Bates speaks with Armon Sharei, Founder and CEO of Portal Biotechnologies, about what happens when AI meets cell engineering, and why point-of-care delivery could make personalised cell programming more practical, scalable, and safer.
The clinical trial ecosystem – a $90 billion engine driving medical innovation is struggling under the burden of its own complexity. Despite significant advancements in therapeutic science, a substantial portion of trial costs is lost to operational inefficiencies, including prolonged manual data reconciliation, challenges in patient recruitment, and reactive regulatory compliance.
The pharmaceutical industry is experiencing a complete digital transformation while organizations have identified drug regulatory affairs as their critical area for maintaining market competitiveness.The pharma regulatory affairs department, which formerly depended on documentation and compliance checks together with manual processes, has transformed itself into a strategic department that uses modern technologies.
Pharmaceutical companies today demonstrate fast growth because their research work shows them how to develop new products through artificial intelligence applications in life science research. Eularis helps organisations to transform their complex data into practical insights which they use to make better decisions and develop products more quickly and achieve superior results for patients.
AI ethics has moved from theory to urgent necessity, especially as AI systems become embedded in healthcare, business decisions, and society at large. In this episode, Dr Andree Bates is joined by Dr Nadia Morozova, founder of Enriched Insights, to unpack what ethical AI really means in practice, and how organisations can innovate quickly without creating risk, bias, or governance failures.
Imagine a tiny medicine that can travel inside your body and go straight to the sick cells. It does not harm the healthy parts of your body.What if doctors could find a disease before you even feel sick?What if treatments could change and adjust inside your body to help you heal faster?
Eularis combines AI, big data, and healthcare expertise to identify true key opinion leaders in the pharmaceutical industry. Using trusted data signals and smarter analysis, Eularish helps teams discover influential experts, improve targeting, and build stronger, evidence-based engagement strategies with confidence.
Let me be direct with you, because many rarely are.
Imagine a tiny medicine that can travel inside your body and go straight to the sick cells. It does not harm the healthy parts of your body.
AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos about biomarker discovery, patient stratification, and why the next breakthroughs come from breaking down data silos across diseases, modalities, and even species.
The pharmaceutical industry is undergoing a rapid transformation, driven in large part by the revolutionary potential of artificial intelligence (AI).AI helps companies study large amounts of data. It helps them find new medicines, improve clinical trials, and make better business decisions.
The pharmaceutical industry is under pressure from every direction. Faster drug development. Tighter regulations. Rising costs. Increasing expectations from patients and healthcare systems.
The AI Strategic Blueprint for Pharma, Eularis identifies a modest shift in awareness and its transformation into results through the strategic alignment of AI with business objectives, the development of an execution plan, and the establishment of business readiness.
I keep finding disruptive AI that solves healthcare marketers’ problems and delivers real ROI in the solutions. But the companies offering them have only 1 or 2 healthcare clients because the healthcare execs are unaware of them. And their existing clients would like it to remain that way, because soon, companies that do not have AI in their centre will be unable to compete.
Write a comment ...